A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis: Broader Clinical Perspectives Beyond the Data and Guideline Recommendations
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis : Broader Clinical Perspectives Beyond the Data and Guideline Recommendations. / Szeimies, Rolf Markus; Dirschka, Thomas; Fargnoli, Maria Concetta; Gilaberte, Yolanda; Hædersdal, Merete; Chavda, Rajeev; Calzavara-Pinton, Piergiacomo.
I: Dermatology and Therapy, Bind 13, Nr. 7, 2023, s. 1409-1421.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - A Review of MAL-PDT for the Treatment Strategy of Actinic Keratosis
T2 - Broader Clinical Perspectives Beyond the Data and Guideline Recommendations
AU - Szeimies, Rolf Markus
AU - Dirschka, Thomas
AU - Fargnoli, Maria Concetta
AU - Gilaberte, Yolanda
AU - Hædersdal, Merete
AU - Chavda, Rajeev
AU - Calzavara-Pinton, Piergiacomo
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population.
AB - Methyl aminolevulinate (MAL) is a topical compound approved for use with photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) and field cancerization in certain countries. There exists a high burden of disease for patients with AK: repeated treatments are required, there is a known risk of progression to keratinocyte carcinoma, and cosmetic appearance is affected. Delivery of PDT using MAL is a flexible treatment strategy available in many forms; red light, daylight, or artificial daylight can be used for illumination, all of which result in high AK clearance rates and low recurrence. MAL-PDT protocols continue to evolve to further improve adherence and treatment outcomes. Here, we used PubMed to search MEDLINE to identify guidelines, consensus recommendations, and studies describing the use of MAL for the treatment of AK. The aim of this targeted review is to consider various MAL-PDT treatment strategies on the basis of published literature, with a focus on personalizing treatment for the heterogeneous AK population.
KW - Actinic keratosis
KW - Artificial daylight photodynamic therapy
KW - Conventional photodynamic therapy
KW - Daylight photodynamic therapy
KW - Field cancerization
KW - Home-based daylight photodynamic therapy
KW - Incubation/illumination times
KW - Methyl aminolevulinate
KW - Metvix
KW - Photodynamic therapy
U2 - 10.1007/s13555-023-00936-w
DO - 10.1007/s13555-023-00936-w
M3 - Review
C2 - 37300793
AN - SCOPUS:85161443665
VL - 13
SP - 1409
EP - 1421
JO - Dermatology and Therapy
JF - Dermatology and Therapy
SN - 2190-9172
IS - 7
ER -
ID: 365663369